⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment just got measured.
4/10 means XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.
Learn about Rx XALKORI® (crizotinib) for treatment of ALK+ or ROS1+ non-small cell lung cancer that has spread to other parts of the body. See risks & benefits.
Industry: Healthcare
xalkori.com1
Structured Data
6
Content Structure
6
Entity Clarity
4
E-E-A-T Signals
6
Technical AEO
2
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
In health and wellness, you're not just selling a product. You're asking someone to trust you with their body.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment.
Scored by Engagemii on June 30, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/xalkori
Cite this score: Engagemii (2026). "AEO Score for XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment." Retrieved from https://engagemii.com/aeo/brands/xalkori
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - AI Brand Discovery and AEO Platform